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Abstract
Background: There is no more effective intervention for secondary prevention of coronary heart disease than
smoking cessation. Yet, evidence about the (cost-)effectiveness of smoking cessation treatment methods for cardiac
inpatients that also suit nursing practice is scarce. This protocol describes the design of a study on the (cost-)
effectiveness of two intensive smoking cessation interventions for hospitalised cardiac patients as well as first results
on the inclusion rates and the characteristics of the study population.
Methods/design: An experimental study design is used in eight cardiac wards of hospitals throughout the
Netherlands to assess the (cost-)effectiveness of two intensive smoking cessation counselling methods both
combined with nicotine replacement therapy. Randomization is conducted at the ward level (cross-over). Baseline
and follow-up measurements after six and 12 months are obtained. Upon admission to the cardiac ward, nurses
assess patients’ smoking behaviour, ensure a quit advice and subsequently refer patients for either telephone
counselling or face-to-face counselling. The counselling interventions have a comparable structure and content but
differ in provider and delivery method, and in duration. Both counselling interventions are compared with a control
group receiving no additional treatment beyond the usual care. Between December 2009 and June 2011, 245
cardiac patients who smoked prior to hospitalisation were included in the usual care group, 223 in the telephone
counselling group and 157 in the face-to-face counselling group. Patients are predominantly male and have a
mean age of 57 years. Acute coronary syndrome is the most frequently reported admission diagnosis. The ultimate
goal of the study is to assess the effects of the interventions on smoking abstinence and their cost-effectiveness.
Telephone counselling is expected to be more (cost-)effective in highly motivated patients and patients with high
SES, whereas face-to-face counselling is expected to be more (cost-)effective in less motivated patients and patients
with low SES.
Discussion: This study examines two intensive smoking cessation interventions for cardiac patients using a multi-
centre trial with eight cardiac wards. Although not all eligible patients could be included and the distribution of
patients is skewed in the different groups, the results will be able to provide valuable insight into effects and costs
of counselling interventions varying in delivery mode and intensity, also concerning subgroups.
Trial registration: Dutch Trial Register NTR2144
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Background
Cardiovascular disease is the leading cause of death and
the second largest source of healthcare costs in Western
Countries [1]. A third of cardiovascular disease mortality
and hospital admissions are caused by coronary heart
disease [2,3]. Smoking cessation after a first coronary
event such as a myocardial infarction significantly
reduces the risk of mortality, hospitalisation rates and
reoccurrence [4-6]. Smoking cessation is thus very rele-
vant to patients with established coronary heart disease.
Nevertheless, over half of those patients who were smo-
kers prior to hospitalisation for coronary heart disease
continue smoking after hospital discharge [7,8]. Cardiac
patients who continue smoking after hospitalisation are
characterised as highly dependent smokers with no or
low future intentions to quit [9]. Earlier research showed
that providing brief cessation support is not effective
enough to help cardiac patients to quit smoking per-
manently [10,11]. Hence, there is a need for more inten-
sive smoking cessation interventions for this patient
group. Interventions proven to increase smoking cessa-
tion rates in hospitalised smokers in general are promis-
ing [11,12]. Compared with the benefits of prevention,
and reduced morbidity and mortality, the healthcare
costs of these interventions are low [13-19].
In the Netherlands, effective interventions for smoking
cardiac patients which also suit nursing practice are
scarce. A cardiac minimal intervention strategy (CMIS)
meant for ward nurses to help smoking patients to quit
was implemented on a large scale in Dutch cardiac
wards [20]. Despite the moderate effect of the CMIS on
smoking behaviour [10], its public health impact was
hindered because of implementation difficulties in prac-
tice [21,22]. Only 28% of all Dutch cardiac ward nurses
consistently and adequately used the CMIS [23]. Nurses
reported barriers to its adequate implementation in hos-
pital units as the difficulty of providing aftercare, lack of
time and other priorities than smoking cessation support
[22-27]. Because of the lack of intensive, and feasible
interventions, many Dutch patients have continued
smoking, resulting in high risks of (re)current coronary
events or mortal closure.
Intensive smoking cessation interventions are, in general,
recommended to cover the need for new (cost-)effective
interventions for smoking cardiac patients [11,28]. Evidence
suggests that interventions combining personalised behav-
ioural counselling with pharmacological treatment are most
likely to increase quitting rates in hospitalised (cardiac)
patients [11,29-33]. It is recommended that this treatment
begins during hospital admission [34] and continues for
more than a month after hospital discharge with numerous
contact moments [29,35]. Preferably, these interventions in-
clude quit advice by cardiologists [36], and a counselling ap-
proach integrating relapse prevention and motivational
interviewing strategies [37-39]. Effectiveness can further be
increased by intervening with regard to specific patient
characteristics associated with a higher risk of continued
smoking after hospitalisation for a cardiac event, such as
symptoms of depression, anxiety and a Type D (distressed)
personality [40-45].
Nicotine Replacement Therapy (NRT) has been shown
to increase quitting rates, either delivered singly [31] or
in combination with behavioural counselling [12,46-49].
The nicotine delivered by NRT has similar or less severe
effects than nicotine obtained through cigarette smoking
and for cardiac patients it has proved to be safer than
smoking [50,51]. NRT provision is recommended for
hospitalised smokers as it aids patients to suppress with-
drawal symptoms [31], irrespective of their intention to
quit [11,34,52].
Reviews of telephone counselling (TC) and face-to-
face counselling (FC), both intensive smoking cessation
behavioural interventions, concluded that they were
equally effective in enhancing quit rates in general popu-
lations [11,32,33]. The significance of TC for cardiac
inpatients is indicated by the fact that it includes mul-
tiple telephone sessions during a follow-up period of
several months [29,53]. A study by Reid et al. (2006)
reported an increase in smoking abstinence rates in car-
diac patients who received TC in addition to usual care
consisting of bedside counselling and NRT use in-
hospital [54]. An earlier study revealed the efficacy of a
nurse-based programme for cardiac inpatients motivated
to quit, including bedside counselling and six follow-up
calls in the four months after discharge. The cessation
rate in the experimental group was twice as high as in
the usual care group [55]. The significance of FC for the
general population of smokers has been reported [32],
though its effectiveness for cardiac patients is less clear.
A meta-analysis showed that psycho-educational pro-
grammes for cardiac patients were effective, revealing a
significant difference in smoking cessation rates between
intensive and less-intensive interventions [56].
TC is less intensive than FC and hence might be more
convenient for certain smokers [57]. There are strong
indications that patients with high quit motivation profit
more from TC than those with low quit motivation [33].
Moreover, low socio-economic status (SES) groups,
often with low quit motivation, may profit more from
FC than higher SES groups [58], although they are
recognised as less successful quitters [59]. Previous stud-
ies indicated that low SES groups have higher coronary
heart disease rates and smoking prevalence than high
SES groups [60,61], and are less likely to quit smoking
successfully while generally revealing lower intentions to
quit [62,63].
The study described here started in 2009. It examines
within the cardiac inpatient setting the (cost-)effectiveness
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and feasibility of TC and FC combined with NRT. The
studies described above provided the rationale for making
such interventions the subject of this evaluation study. TC
and FC incorporate the same elements but differ in deliv-
ery mode and intensity. This paper describes the aims, hy-
potheses and design of the study, the intervention
components of TC and FC, and the inclusion rates of the
study participants and their baseline characteristics. The
effectiveness study specifically compares health outcomes
and smoking cessation outcomes, whereas the cost-
effectiveness study also compares these outcomes with the
costs of the interventions, including usual care.
On the basis of previous studies we expect to find 55%
quitters at 12 months in both intervention groups against
35% in the control group [10,29,35,64]. Since reviews con-
cluded that both interventions (TC and FC) were equally
effective in general populations [32,33,65], we expect to
find significant differences in smoking abstinence between
usual care on the one hand and experimental conditions
on the other. We furthermore expect to find differential
effects within the experimental conditions: it is hypothe-
sised that low SES groups profit more from FC compared
with higher SES groups. It is also hypothesised that FC is
more (cost-)effective for patients with low quit motivations,
whereas TC is more (cost-)effective for patients with high
quit motivations and a higher SES.
Methods/design
Setting
Forty-six cardiac wards of urban, leading clinical and
academic hospitals throughout the Netherlands were
approached for potential participation. Thirteen of these
wards that did not offer any form of smoking cessation
intervention to cardiac patients (unlike care as usual)
were recruited. Five of these wards were still rejected by
the research team because of incomparability with the
other wards in terms of their constitution (i.e. they had a
combined heart and lung unit). The remaining eight car-
diac wards were accepted for the study.
In line with the Dutch Medical Research Ethics
Committee (MERC) rules [66] the study protocol was
submitted for approval to the MERC of the VU medical
center Amsterdam. After approval by this MERC (MEC
2009/215; NL27637.029.09), the MERCs and/or Board of
Directors of each hospital endorsed execution of the
study. The study was registered with the Dutch Trial
Registration (NTR2144).
Design
An experimental study using cross-over randomization
at the ward level with a baseline measurement at hos-
pital admission and post-measurements at six and 12
months after baseline was conducted. All cardiac wards
first provided care as usual and subsequently the two
experimental conditions one after the other. Table 1
shows a schematic representation of the serially imple-
mented conditions. After completion of care as usual,
four of the cardiac wards started implementing TC, and
after its completion they implemented FC. The other
four cardiac wards implemented the experimental con-
ditions in reverse order. After each condition there was
a one month period without inclusion of any patient.
Sample size calculations
Power and sample size calculations were conducted for the
main outcome, seven-day point prevalence abstinence
(PPA) after 12 months. Power calculations (one-sided;
p<0.05, Power= 0.80) showed that 193 patients per condi-
tion were needed to detect significant differences in PPA
and possible interaction effects of the interventions with
motivation to quit and SES. Advanced statistical methods,
however, allowed adjustment for potential baseline con-
founding variables and improved the statistical power.
Therefore, the required sample size was reduced by 30%
[67], resulting in the need for N=135 in each condition.
Assuming 15% attrition at the 12-month follow up, 155
patients per condition needed to be recruited, totalling 465
patients for the three conditions.
Baseline procedure
After approval was received from the Board of Directors
and Ethical Review Committees of each hospital, the face-
to-face counsellors (16 in total, i.e. two nurses from each of
the cardiac wards that participated in the study) received
training to provide FC. Ward nurses and cardiologists
received written and oral instructions of the study with a
written stepwise protocol and information sheet on the in-
clusion process of eligible patients, a flowchart with
instructions and addresses for referral. Over an 18-month
period beginning in December 2009, the nurses asked all
patients admitted to the cardiac ward if they had smoked
in the month prior to admission. If the answer was yes, the
nurses reviewed the information sheet with the inclusion
criteria, approached medically stable patients at the bed-
side, provided the necessary information about the study
to patients, and invited eligible smoking patients to take
part in the study. If patients agreed to take part, the nurses
asked them to sign an informed consent form.
Table 1 Outline of the study design
Cardiac wards 1 to 4: Cardiac wards 5 to 8:
O1 UC O2 O3 O1 UC O2 O3
O1 FC O2 O3 O1 TC O2 O3
O1 TC O2 O3 O1 FC O2 O3
O1: baseline measurement with questionnaire; UC Usual Care condition; FC
Face-to-face Counselling experimental condition; TC Telephone Counselling
experimental condition; O2: six months follow-up measurement by telephone
interview; O3: 12 months follow-up measurement by telephone interview and
biomedical measurements (saliva, cholesterol, blood pressure).
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Subsequently, at hospital admission, nurses administered
the questionnaire to patients and registered relevant pa-
tient data on a separate form. Nurses also produced a sum-
mary of patients’ prescribed medication from their case
history.
Participants: inclusion and characteristics
Inclusion criteria for patients were: smoking on average
≥5 cigarettes per day in the month prior to admission or,
if not smoking, having quit smoking less than four
weeks before admission; being ≥18 years of age; being
admitted to the cardiac ward for less than 96 h and
being hospitalised because of a coronary heart disease
(acute coronary syndrome, stable angina, and other
forms of chronic and acute heart diseases) following the
standards of the ICD-10 [68]. Exclusion criteria were
language limitations that would impede completion of
the self-administered questionnaire, a medically unstable
cardiac situation or cognitive impairments.
As shown in Figure 1, 245 cardiac patients were included
in the usual care condition, 223 in the experimental
condition of TC, and 157 cardiac patients in the experimen-
tal condition of FC. With inclusion rates varying from 42 to
121 patients per cardiac ward, rates varied considerably per
cardiac ward (see Table 2).
As presented in Table 3, patients were predominantly
male with a mean age of 57 years. Education levels were
relatively equally distributed over low, intermediate and
high education. Most of the patients had an admission
diagnosis of acute coronary syndrome (ACS) or had
been diagnosed with ACS previously and were admitted
to the hospital for treatment with a percutaneous coron-
ary intervention (PCI) or a coronary artery bypass graft
(CABG). During the six months prior to admission a few
patients had been admitted to the hospital owing to a
cardiac event. Nicotine dependence was moderate, and
patients reported smoking 21 cigarettes on average per
day before hospital admission. Although the majority of
the patients had not made any quit attempt over the past
12 months, one-third reported on admission that they
had not smoked over the past seven days. There were no
significant differences between the three groups in terms
Figure 1 Flow diagram of the experimental study testing the effectiveness of two intensive smoking cessation treatment methods in
cardiac patients.
Berndt et al. BMC Cardiovascular Disorders 2012, 12:33 Page 4 of 12
http://www.biomedcentral.com/1471-2261/12/33
of demographic characteristics. Nicotine dependence
was significantly higher, however, in the control group
than in the experimental groups.
Interventions
Standard in-hospital smoking cessation care (usual care)
All patients received standard in-hospital treatment for
smoking cessation which consisted of an assessment of
their smoking behaviour and a personalised brief quit
advice. Quit advice was largely provided by cardiologists
(and occasionally by ward nurses) while patients were
on the cardiac ward.
Telephone counselling (TC) or face-to-face counselling (FC)
There were two experimental conditions, one consisting
of TC and one of FC. The two counselling methods
started within one week after the inclusion of the patient
and had a comparable structure and content. Nurses on
cardiac wards followed the Ask-Advice-Refer strategy
[69,70] prior to the counselling sessions. In accordance
with this strategy, patients’ smoking behaviour was first
assessed. Second, smoking patients were advised to quit,
and third, they were referred to health professionals pro-
viding TC or FC outside the ward. Furthermore, nurses
provided nicotine patches and information on their ne-
cessity and application to eligible patients. The counsel-
ling was provided by professional counsellors: in the TC,
these were counsellors from the Dutch Expert Centre
for Tobacco Control (STIVORO); in the FC, these
were cardiac nurses trained in providing smoking ces-
sation counselling. All counsellors received financial
compensation. The main differences between the
Table 3 Baseline characteristics of the total sample and comparability of the three groups
Total (N= 625) UC (n = 245) TC (n= 223) FC (n = 157)
Variables N (%)/M (SD) N (%)/M (SD) N (%)/M (SD) N (%)/M (SD)
Gender (male) 457 (73.1%) 183 (74.7%) 163 (73.1%) 111 (70.7%)
Age 55.8 (11.08) 55.8 (11.88) 55.31 (10.53) 56.5 (10.57)
Marital status
Married with/without children 413 (67.8%) 160 (67.5%) 151 (68.5%) 102 (66.7%)
Single/divorced/widow 196 (32.2%) 77 (32.5%) 68 (31.5%) 31 (33.3%)
Education level a
Low education 244 (40.5%) 97 (41.8%) 83 (38.1%) 64 (41.8%)
Intermediate education 233 (38.6%) 83 (35.8%) 88 (40.4%) 62 (40.5%)
High education 126 (20.9%) 52 (22.4%) 47 (21.6%) 27 (17.6%)
Disease diagnosis and/or treatment b
ACS (unstable angina, non-stemi, stemi) 530 (84.8%) 210 (85.7%) 191 (85.7%) 129 (82.2%)
Stable angina 53 (8.5%) 16 (6.5%) 23 (10.3%) 14 (8.9%)
Other diagnosis/unknown 42 (6.7%) 19 (7.8%) 9 (4.0%) 14 (8.9%)
Previous hospital admission (yes) 122 (20.2%) 48 (20.7%) 37 (17.0%) 37 (24.0%)
Nicotine dependence c 5.25 (2.18) 4.99 (2.28)* 5.27 (2.14) 5.62 (2.01)
Average cigarettes per day 21.13 (13.04) 19.69 (10.64) 21.83 (15.78) 22.31 (11.82)
Seven-day abstinence at admission (PPA) (yes) 183 (29.3%) 79 (34.3%) 64 (29.4%) 40 (27.6%)
Quit attempts over the past 12 months (yes) 188 (30.5%) 87 (36.3%) 55 (24.9%) 46 (29.6%)
Intention to quit d 7.53 (2.17) 7.54 (2.30) 7.55 (2.1) 7.49 (2.06)
Note. Numbers may vary due to missing data.
a low education = primary and basic vocational school, intermediate education = secondary vocational school and high school degree, high education= higher
vocational school degree, college or university degree; b ACS = acute coronary syndrome, (non-)stemi = (non-) ST elevation myocardial infarction; c range from
0= low nicotine dependence to 10 = high nicotine dependence; d range from 0=weak intention to 10 = strong intention.
* p-value is significant at the 0.05 level.
Table 2 Differences in inclusion rates per cardiac ward
(N= 625)
Total UC group TC group FC group
N (%) N (%) N (%) N (%)
Cardiac ward 1 42 (6.7) 21 (8.6) 20 (9.0) 1 (0.6)
Cardiac ward 2 97 (15.5) 32 (13.1) 40 (17.9) 25 (15.9)
Cardiac ward 3 121 (19.4) 50 (20.4) 38 (17.0) 33 (21.0)
Cardiac ward 4 91 (14.6) 32 (13.1) 31 (13.9) 28 (17.8)
Cardiac ward 5 115 (18.4) 39 (15.9) 36 (16.1) 40 (25.5)
Cardiac ward 6 52 (8.3) 21 (8.6) 23 (10.3) 8 (5.1)
Cardiac ward 7 64 (10.2) 30 (12.2) 25 (11.2) 9 (5.7)
Cardiac ward 8 43 (6.9) 20 (8.2) 10 (4.5) 13 (8.3)
Note. Cardiac ward 1 is located in an academic university hospital. All other
cardiac wards are located in leading clinical hospitals.
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counselling methods were the delivery mode and in-
tensity of the counselling. TC lasted for three months
and consisted of seven telephone sessions of 10 to15
min (two hours in total). FC also lasted three months,
consisted of six face-to-face sessions of 45 min and
ended with a follow-up call eight weeks after the last
session (4.75 h in total).
Existing protocols of TC and FC developed by the
Dutch Expert Centre for Tobacco Control for the gen-
eral smoking public were used, though adapted and fine-
tuned to the situation of cardiac patients. The protocols
focused on important determinants of smoking cessation
and relapse such as self-efficacy and smoking-related
attitudes [32,33,58]. The underlying theoretical methods
of the two counselling methods were comparable and
incorporated strategies based on the principles of motiv-
ational interviewing [38], enhancement of self-efficacy
[71,72], goal-setting [73] and relapse prevention [74]. In
contrast to TC, patients who were referred to the FC
condition additionally received a workbook from their
face-to-face coach. For each session the workbook con-
tained the most relevant information and a few pieces of
homework such as developing personalised strategies for
dealing with high-risk situations or developing a perso-
nalised emergency plan for how to avoid absolute relapse
when experiencing a lapse.
The design and main content of the TC and FC ses-
sions are presented in Table 4. In seven successive coun-
selling sessions, the counsellor assisted the patient to
become smoke-free and/or maintain his or her smoking
abstinence. The underlying theoretical model of the
counselling sessions was the Transtheoretical Model by
Prochaska and Diclemente [75]. This model posits that
health behaviour change involves progress through five
stages. The first three stages are pre-action stages (pre-
contemplation, contemplation, preparation) where smo-
kers have no or a weak intention to quit or prepare a
quit attempt. The last two stages are post-action stages
(action, maintenance) where smokers genuinely quit
smoking and ideally maintain their abstinence. In line
with each of these stages, the counsellor provided stage-
matched information and applied strategies tailored to
each individual patient in order to move forward from
one stage to the next, to arrive finally at the smoking
cessation maintenance stage.
Fine-tuning of TC and FC was directed at specific
characteristics of cardiac patients previously shown to be
impediments to smoking cessation (depression, anxiety,
and Type D personality) [41,76-79], and targeted group-
specific predictors of relapse [80-83]. A substantial num-
ber of the patients had not smoked since hospital admis-
sion. Some of them considered this temporary smoking
restriction as a serious quit attempt, whereas others
intended to resume smoking as soon as possible. To in-
tegrate these features as intervention components, pro-
tocols were adapted by the researchers including tips
and tricks on the characteristics and particular situation
of cardiac patients. The protocol contained information
on how the content of the counselling sessions might
vary and how it could be adjusted to the particular needs
Table 4 Main protocol of the Telephone Counselling (TC) and Face-to-face Counselling (FC) sessions for smoking
cardiac patients
Preparation Action Maintenance
Session 1
(Pre-) contemplation:
Discussing
the harmful
effects of
nicotine
and the vicious
cycle of
nicotine
dependence.
Striking a balance
between pros
and cons of
smoking
and cessation.
Session 2
Preparation:
Helping the
patient to
make the
decision to
quit smoking
and prepare
for quitting
by providing
information
on nicotine
withdrawal.
Session 3
Action:
Providing
information
about the
desire to
smoke.
Teaching
strategies
for dealing
with craving
and withdrawal
symptoms.
Session 4
Action:
Providing
information
about tempting
(high risk)
situations.
Teaching
coping
strategies
for tempting
situations.
Session 5
Maintenance:
Providing
information
about relapse
and discussing
strategies for
how to prevent
relapse to smoking.
Developing an
emergency plan
in case the patient
lapses.
Session 6
Maintenance:
Choosing
and discussing
a theme
relevant to
the patient
(i.e. stress,
negative
affect social
pressure or
controlling
weight)
to avoid relapse
to smoking.
Session 7
Maintenance:
Follow-up
call. Evaluation
of the cessation
progress and
discussing relapse
prevention
strategies.
All sessions
• Boost patients’ motivation to quit smoking and/or maintain abstinence;
• Adapt the content of the session to the particular situation and need of the patient;
• Take into account that numerous patients quit at hospitalisation and retrospectively discuss pre-action stages to enhance consciousness of smoking
cessation.
TC: 15 min
FC: 45 min
week 1
TC: 15 min
FC: 45 min
week 2
TC: 15 min
FC: 45 min
week 3
TC: 15 min
FC: 45 min
week 4
TC: 15 min
FC: 45 min
week 5
TC: 15 min
FC: 45 min
week 7
TC: 15 min
FC: 15 min
week 12
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of the patient. An additional three-page information
folder was developed and provided to cardiac patients in
the intervention groups. This folder provided informa-
tion and strategies on avoiding and dealing with risk
situations for smoking where patients might experience
negative affect and social inhibition, key characteristics
of a Type D personality.
Counselling combined with nicotine replacement therapy
Reasons for the combination therapy of TC or FC with
NRT in the study reported here were that antidepres-
sants for smoking cessation (e.g. Bupropion) cannot be
prescribed for all patients [84], NRT has been proven to
be safe for cardiac patients [46,51] and equally effective
as medical pharmacotherapy [31,84]. Cardiologists from
the participating cardiac wards agreed on the prescrip-
tion of transdermal nicotine patches for cardiac patients.
The pharmacological therapy was therefore similar for
all patients, essential to guarantee validity and enable
conclusions to be drawn on the effectiveness of TC and
FC. Owing to possible contra-indications in cardiac
patients, cardiologists had to approve the delivery of
nicotine patches for each individual patient. Eligible
patients received NRT when indicated and when they
smoked more than 10 cigarettes a day before hospital ad-
mission [85]. As treatment of eight weeks has been shown
to be as efficacious as longer treatment periods [30],
patients received the patches for eight weeks (at no cost).
Recruitment and training of counsellors
Professional telephone counsellors from the Dutch Ex-
pert Centre for Tobacco Control provided the TC
(n = 4). The researchers provided additional training of
four hours to the telephone counsellors. This training
was necessary to inform the counsellors about specific
patient characteristics.
To recruit face-to-face counsellors from the participat-
ing hospitals two cardiac nurses per nursing unit were
invited to become professional smoking cessation coun-
sellors (n = 16). An expert team of senior trainers from
the Dutch Expert Centre for Tobacco Control provided
the training to the cardiac nurses. The training of face-
to-face counsellors consisted of eight sessions of four
hours spread over four days with a break of six weeks
between the first and the last training sessions.
Pilottesting of materials
For a small number of patients (n = 6), face-to-face and
telephone counsellors (n = 4) and cardiac nurses of the
participating wards (n = 6), materials (questionnaires for
patients, additional protocols for nurses and counsellors,
workbook for patients, folder for patients) were pilot-
tested by means of in-depth interviews. Even though the
Dutch Expert Centre for Tobacco Control [58] had
already evaluated their training for counsellors in gen-
eral, the training was evaluated on a small scale, and fo-
cused on the counselling of cardiac patients in order to
fine-tune the interventions for this target group. The
pilot interview with cardiac patients and counsellors
resulted in some amendments to the content and the
adaptation of some of the materials in terms of sentence
structure.
Follow-up procedures
Six months after discharge (T1) patients were inter-
viewed by telephone by members of a professional call
agency to obtain follow-up data (see Figure 1). The 12-
month follow-up measurements are still in progress
(T2). The smoking cessation outcomes are assessed by
means of validated reliable questions [86-88]. Telephone
interviews are conducted in order to decrease the likeli-
hood of attrition [10,89]. One postal reminder letter is
sent 10 days before each of these telephone interviews.
All patients who complete the 12-months interview are
also invited to the hospital for biomedical tests of blood
pressure, cholesterol and saliva.
Cardiac nurses are responsible for conducting the
blood pressure tests, the cholesterol tests and the coti-
nine tests at the cardiac nursing ward. Cardiac nurses
ask patients while conducting the blood pressure test if
they have been smoking over the past seven days to as-
sess point-prevalence abstinence. If patients claim not to
have smoked any cigarettes, their saliva is tested on coti-
nine residuals by means of the NicAlert Cotinine Test
Strip to test whether the self-reported smoking behavior
is accurate. Results can be either positive (no cotinine
detected) or negative (cotinine detected). Cardiac nurses
register the results of the blood pressure, cholesterol and
cotinine tests and send the findings to the research team.
Measures
Effectiveness study: outcome measures
The primary outcome is seven-day point prevalence ab-
stinence from smoking (PPA) after six and 12 months
(0 = smoking;1 = non-smoking). PPA is the main out-
come since it is considered to be the most sensitive and
valid measure of smoking cessation [87]. Secondary out-
comes are continued abstinence, quit attempts, and
health outcomes. Health outcomes measured at T1 and
T2 are new coronary events and hospital readmissions
for coronary events. Cholesterol ratio and blood pressure
are only assessed at T2 at the patients’ outpatient clinic.
Intention to treat analyses will be applied [88] and
smoking status is verified at T2 by a saliva sample. For
these patients the outcome of the saliva test (detection
of cotinine) will be taken as a control variable in the
analyses to confirm the self-reported response of the
smoking behaviour. This test has been proven to be a
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valid and reliable method for verification of smoking sta-
tus [90].
Cost-effectiveness study: Cost factors and resource use
At T1 and T2, information on the other health eco-
nomic outcomes is assessed for the past three months:
visits to the general practitioner, cardiology outpatient
visits, health related costs, rehospitalisations in the past
six months, informal care costs, and health-related qual-
ity of life. Effects on productivity are measured in terms
of absence from work owing to illness [91].
Resource use specifically for the interventions was
recorded prospectively by the counsellors. This included
counsellor time, use of materials, use of nicotine replace-
ment patches and specialist time involved in cessation
advice [92-94].
Other measures
A process evaluation was conducted at six-month fol-
low-up in which patients were asked about usefulness of
the interventions in total, their separate elements and
patients’ adherence to NRT and counselling sessions.
The baseline measurement and both post-tests also as-
sess factors that are related to smoking cessation and/or
relapse among this patient population. These include
demographics; smoking-related factors [95]; disease-
related factors; psychological states including depression
and anxiety [96], Type D personality [97]; smoking
cessation-related cognitions and motivation to quit
[10,98]. To measure smoking-related cognitions and mo-
tivation to quit, existing questionnaires are used [86,99]
which are based on previous social-cognitive models
[75,100,101]. To assess the expected differential effects
of the interventions for SES, SES is assessed in terms of
education level and income [86].
Statistical analyses
Data is analyzed with SPSS. Descriptive statistics are used
to describe the sample, and to compare the groups at
baseline, ANOVA analyses and chi-square analyses are ap-
plied. In order to determine possible selective loss at fol-
low-up, attrition analyses are conducted. The effects of
the interventions on smoking cessation outcomes and
possible interaction effects (condition * SES/condition *
intention to quit) are tested by means of logistic regression
analyses. The hospital group size of eight is inadequate for
reliably testing the existence of variation by a multi-level
model [102]. Therefore, a fixed-effect regression approach
is likely to be used to eliminate possible hospital-level
effects. Baseline variables are included as covariates to cor-
rect for possible baseline differences, to reduce unex-
plained variance and to increase the power of the tests. To
analyse effects on rehospitalisation, new cardiac events,
number of visits to the cardiologist and cardiovascular-
related death, multiple regression analyses are used.
Effects of the interventions on blood pressure, TC/HDL
cholesterol, and intentions to quit are tested by means of
repeated measures analyses of covariance. Logistic regres-
sion analyses are also used to examine predictors of smok-
ing cessation overall and within subgroups. Patients in the
experimental groups are compared by paired sample t-
tests for level of appreciation of the intervention. Eco-
nomic evaluation analyses are performed by applying spe-
cific cost-effectiveness calculation formulas. Moreover, a
health-economic Markov Model is built to estimate long-
term costs and health effects.
Discussion
Two different interventions were designed that com-
bined intensive smoking cessation counselling – either
delivered face-to-face or by telephone – and NRT. The
interventions were designed to overcome the weaknesses
of usual care and minimal interventions being too brief
and not including recommended elements of smoking
cessation treatment guidelines [30]. To overcome a sec-
ond drawback of current interventions, i.e. the imple-
mentation and feasibility difficulties reported by ward
nurses in terms of providing brief support on smoking
cessation, the counselling (TC and FC) was delegated to
smoking cessation professionals tasked with formal re-
sponsibility who had enough time to spare. As nurses
applied the Ask-Advice-Refer approach, attention was
paid to patients’ smoking behaviour at hospital admis-
sion while being referred to external professionals. This
approach was assumed to be feasible in busy nursing
units where nurses lack time and skills to provide smok-
ing cessation support themselves [69,70]. Offering smok-
ing cessation treatment as an adjunct to hospital-
initiated programmes shortly after hospital discharge
lastly overcame the limitation of cardiac rehabilitation
programmes which usually do not start within the first
four weeks after discharge and only pay very brief atten-
tion to smoking cessation.
Study strengths
This study is a multi-centre trial carried out in eight
hospital cardiac wards from different geographical
regions of the Netherlands. Most randomised controlled
trials on preventative interventions for smoking cardiac
patients are conducted in only one or a few hospitals, so
the information gathered from eight hospital wards
improves generalisation of the study results. Cross-over
randomisation was conducted at the ward level by se-
quentially implementing the conditions, which was done
to overcome problems related to traditional randomised
controlled trials. This design meant contamination be-
tween patients was avoided, as well as learning effects
on ward nurses. The chosen design also circumvented
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nurses’ mistakes in performing the interventions. More-
over, the experimental design allowed us to control for
confounding effects such as seasonal influences or other
extraneous events. Last but not least, a cost-effectiveness
study was carried out alongside the standard clinical
trial, which allows us to estimate the additional costs
and benefits of the interventions compared with a con-
trol group receiving usual care.
Methodological considerations
Although we made efforts to include all eligible smoking
cardiac patients within the a time frame of one year and
to register data on those eligible patients not enrolled in
the study, the baseline results suggested that neither task
was performed as intended. Nurses were asked to register
the refusals of patients not enrolled in the study but this
was not well done. There are indications that in some hos-
pitals there were more refusals than in others. The inclu-
sion period was expanded to 18 months as the inclusion
of smoking cardiac patients in hospital cardiac wards took
longer than expected. Low inclusion rates were related to
ward factors such as insufficient patient admissions, few
patients who met the inclusion criteria of the research,
and limited admission capacities of cardiac wards. Other
factors hindering patient inclusion in the study were high
workloads on cardiac wards, non-collaborative nursing
teams, and little interest in smoking cessation pro-
grammes at the general hospital. These factors have previ-
ously been shown to impede implementation of smoking
cessation interventions in cardiac wards [103-105]. The
inclusion rate in the FC group was relatively low which
might be related to its time-consuming treatment form,
resulting in a skewed distribution of patients with 157
patients in the FC group, 223 in the TC group and 245 in
the UC group. Moreover, inclusion rates varied consider-
ably between cardiac wards and this suggests the likeli-
hood of non-representative outcomes of the effectiveness
study for those cardiac wards that only included a few
patients per group. We also note that there were differ-
ences in nicotine dependence between the experimental
groups and the usual care group, as nicotine dependence
was significantly higher in the experimental groups.
Altogether these considerations pose the limitation of a
selective sample of cardiac patients, implying the poten-
tially limited generalisability of the study results.
Conclusion
Feasible evidence-based smoking cessation intervention
approaches are required to support cardiac patients in
quitting smoking in order to reduce future risks of car-
diac events. Since subgroups may profit more from a dif-
ferent type of intervention and should receive the most
(cost-)effective one, this study compares two intensive
counselling methods - one provided face-to-face and the
other by telephone - to each other and to usual care on
their costs and effects on smoking abstinence. Although
the inclusion period was expanded and not all eligible
patients could be included, the results of this multi-
centre trial will be able to provide valuable insight into
the (cost-)effectiveness of both counselling
interventions.
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